Aptinyx (NASDAQ:APTX) Releases Quarterly Earnings Results, Beats Expectations By $0.02 EPS

Aptinyx (NASDAQ:APTXGet Rating) released its quarterly earnings data on Thursday. The company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.02, Fidelity Earnings reports. During the same quarter in the prior year, the firm posted ($0.22) EPS.

NASDAQ APTX traded up $0.10 on Friday, hitting $0.70. 136,370 shares of the stock were exchanged, compared to its average volume of 312,910. The company has a debt-to-equity ratio of 0.15, a quick ratio of 20.18 and a current ratio of 20.18. The stock has a fifty day moving average price of $1.78 and a two-hundred day moving average price of $2.43. The firm has a market capitalization of $47.40 million, a P/E ratio of -0.59 and a beta of 1.46. Aptinyx has a 52-week low of $0.57 and a 52-week high of $4.73.

Several equities research analysts recently weighed in on APTX shares. SVB Leerink reduced their price target on shares of Aptinyx from $10.00 to $4.00 and set an “outperform” rating on the stock in a research report on Thursday, April 21st. Truist Financial reduced their price target on shares of Aptinyx from $12.00 to $5.00 and set a “buy” rating on the stock in a research report on Friday, April 8th. Zacks Investment Research cut shares of Aptinyx from a “buy” rating to a “hold” rating in a research report on Friday, April 22nd. BMO Capital Markets reduced their price target on shares of Aptinyx from $12.00 to $6.00 in a research report on Friday, April 8th. Finally, HC Wainwright reduced their price target on shares of Aptinyx from $8.00 to $2.00 and set a “buy” rating on the stock in a research report on Thursday, April 14th. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $3.88.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Millennium Management LLC boosted its stake in shares of Aptinyx by 19.7% during the fourth quarter. Millennium Management LLC now owns 1,246,945 shares of the company’s stock valued at $3,329,000 after purchasing an additional 205,553 shares during the period. Vanguard Group Inc. boosted its stake in shares of Aptinyx by 8.4% during the first quarter. Vanguard Group Inc. now owns 1,964,058 shares of the company’s stock valued at $4,459,000 after purchasing an additional 152,943 shares during the period. Northern Trust Corp boosted its stake in shares of Aptinyx by 203.7% during the first quarter. Northern Trust Corp now owns 219,698 shares of the company’s stock valued at $498,000 after purchasing an additional 147,357 shares during the period. Susquehanna International Group LLP boosted its stake in shares of Aptinyx by 56.8% during the fourth quarter. Susquehanna International Group LLP now owns 243,275 shares of the company’s stock valued at $650,000 after purchasing an additional 88,141 shares during the period. Finally, Cetera Advisor Networks LLC purchased a new stake in shares of Aptinyx during the first quarter valued at $92,000. 55.97% of the stock is owned by institutional investors.

Aptinyx Company Profile (Get Rating)

Aptinyx Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II/b clinical trial for treating fibromyalgia.

See Also

Earnings History for Aptinyx (NASDAQ:APTX)

Receive News & Ratings for Aptinyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptinyx and related companies with MarketBeat.com's FREE daily email newsletter.